Jiangsu Hengrui Pharmaceuticals revenue and financials
¥47.20Change from previous close: +3.46%Absolute change: +¥1.58
In the fiscal year ended December 2025, Jiangsu Hengrui Pharmaceuticals reported revenue of ¥31.63B (+13.02% year over year). Net income was ¥7.71B, a net margin of 24.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +13.02%
- 2025 vs 2024
- Net income growth
- +21.69%
- 2025 vs 2024
- Net margin
- 24.4%
- 2024: 22.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | 31,629 | 27,985 | 22,820 | 21,275 |
| Cost of revenue | 4,363 | 3,848 | 3,525 | 3,487 |
| Gross profit | 27,267 | 24,136 | 19,295 | 17,789 |
| Selling, general and administrative | 7,358 | 7,221 | 6,469 | 6,209 |
| Research and development | 6,961 | 6,583 | 4,954 | 4,887 |
| Operating income | 8,596 | 6,803 | 4,626 | 3,345 |
| EBIT | 8,722 | 7,175 | 4,673 | 3,975 |
| EBITDA | 9,567 | 7,951 | 5,378 | 4,553 |
| Interest expense | 14.3 | 5.6 | 5.9 | 6.5 |
| Pre-tax income | 8,708 | 7,170 | 4,667 | 3,968 |
| Income tax | 991 | 833 | 389 | 153 |
| Net income | 7,711 | 6,337 | 4,302 | 3,906 |
| Net income to common shareholders | 7,711 | 6,337 | 4,302 | 3,906 |
| Basic EPS | 1.19 | 1.00 | 0.68 | 0.61 |
| Diluted EPS | 1.18 | 1.00 | 0.68 | 0.61 |
| Average shares (basic) | 6,480 | 6,337 | 6,327 | 6,404 |
| Average shares (diluted) | 6,535 | 6,337 | 6,327 | 6,404 |